AGASTHI fillers are based on crosslinked hyaluronic acid, engineered to deliver optimized viscoelasticity, cohesion, and tissue integration.
Our development process focuses on balancing lifting capacity, flexibility, and durability while minimizing formulation stress on surrounding tissues.
MULTIPLE SWELLING FORMULATION TECHNOLOGY
MSFT is a method of blending multiple swelling ratios, and it maintains excellent volume effects while ensuring safety by minimizing crosslinking agents Minimal use of crosslinking agents.
SINCE AGASTHI IS PRODUCED BY MSFT TECHNOLOGY, IT RESULTS IN HIGH TISSUE ADHESION AND EXCELLENT VOLUME EFFECT.
AGASTHI is made up of hyaluronic acid gels with a high ratio of hydrophilic that provides an excellent volume effect.
AGASTHI has outstanding tissue adhesion with high cohesion.
AGASTHI IS AN INNOVATIVE PRODUCT THAT MINIMIZES TOXICITY AND INCREASES SAFETY WITH THE USE OF ITS UNIQUE TECHNOLOGY, MSFT.
AGASTHI minimizes free radical formation by significantly reducing proteins that may cause hypersensitivity reactions.
Moreover, AGASTHI has a low unit level of endotoxin which holds an outstanding safety profile.
The finding from the in-vitro decomposition process substantiates that AGASTHI has 4 times longer body duration than any product.
AGASTHI COMBINES ALL THE NECESSARY QUALITIES: SAFETY, EFFICACY, SUSTAINABILITY
